Skip to main content
SpringerLink
Log in

A nationwide survey among emergency physicians and oncologists to improve the management of immune checkpoint inhibitors toxicity

  • Letter to the Editor
  • Published:
Supportive Care in Cancer Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Guven DC, Sahin TK, Aksun MS, Taban H, Aktepe OH, Aksu NM, Akkaş M, Erman M, Kilickap S, Dizdar O, Aksoy S (2021) Evaluation of emergency departments visits in patients treated with immune checkpoint inhibitors. Support Care Cancer 29(4):2029–2035. https://doi.org/10.1007/s00520-020-05702-8

    Article  PubMed  Google Scholar 

  2. Lash RS, Bell JF, Reed SC, Poghosyan H, Rodgers J, Kim KK, Bold RJ, Joseph JG (2017) A Systematic review of emergency department use among cancer patients. Cancer Nurs 40(2):135–144. https://doi.org/10.1097/NCC.0000000000000360

    Article  PubMed  PubMed Central  Google Scholar 

  3. Casanovas BM (2019) Critical review of emergency department management of chemotherapy complications in cancer patients. Eur J Cancer Care (Engl) 28(2):e12974. https://doi.org/10.1111/ecc.12974

    Article  Google Scholar 

  4. Haslam A, Prasad V (2019) Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs. JAMA Netw Open 2(5):e192535. https://doi.org/10.1001/jamanetworkopen.2019.2535

    Article  PubMed  PubMed Central  Google Scholar 

  5. Chhabra N, Kennedy J (2021) A review of cancer immunotherapy toxicity: immune checkpoint inhibitors. J Med Toxicol 17(4):411–424. https://doi.org/10.1007/s13181-021-00833-8

    Article  PubMed  Google Scholar 

  6. Chen B, Kanaan C, Jaiyesimi I, Ezekwudo D, Swor R (2020) Clinical characteristics of patients with cancer presenting to the emergency department and their use of emergency medical service transport. Prehosp Emerg Care 24(6):813–821. https://doi.org/10.1080/10903127.2020.1718258

    Article  PubMed  Google Scholar 

  7. Legramante JM, Pellicori S, Magrini A, Frittelli T, Formica V, Roselli M (2018) Cancer patients in the emergency department: a “nightmare” that might become a virtuous clinical pathway. Anticancer Res 38(11):6387–6391. https://doi.org/10.21873/anticanres.12998

    Article  PubMed  Google Scholar 

  8. Peyrony O, Tieghem Y, Franchitti J, Ellouze S, Morra I, Madelaine-Chambrin I, Flicoteaux R, Baroudjian B, Azoulay E, Chevret S, Fontaine JP (2019) Immune checkpoint blockade toxicity among patients with cancer presenting to the emergency department. Emerg Med J 36(5):306–309. https://doi.org/10.1136/emermed-2018-208091

    Article  PubMed  Google Scholar 

  9. El Majzoub I, Qdaisat A, Thein KZ, Win MA, Han MM, Jacobson K, Chaftari PS, Prejean M, Reyes-Gibby C, Yeung SJ (2019) Adverse effects of immune checkpoint therapy in cancer patients visiting the emergency department of a comprehensive cancer center. Ann Emerg Med 73(1):79–87. https://doi.org/10.1016/j.annemergmed.2018.04.019

    Article  PubMed  Google Scholar 

  10. Nguyen EE, Winokur E (2019) Immunotherapy adverse events: an emergency nursing perspective. J Emerg Nurs 45(6):699–706. https://doi.org/10.1016/j.jen.2019.06.005

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. School of Emergency Medicine, University of Turin, Turin, Italy

    Jacopo Davide Giamello

  2. Department of Emergency Medicine, Santa Croce e Carle Hospital, Cuneo, Italy

    Giuseppe Lauria & Bartolomeo Lorenzati

  3. Department of Medical Oncology, University of Pisa, Pisa, Italy

    Andrea Antonuzzo

  4. Department of Medical Oncology, University of Brescia, Brescia, Italy

    Paolo Bossi

  5. Department of Medical Oncology, Santa Croce e Carle Hospital, Cuneo, Italy

    Gianmauro Numico

Authors
  1. Jacopo Davide Giamello
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Giuseppe Lauria
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Andrea Antonuzzo
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Paolo Bossi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Bartolomeo Lorenzati
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Gianmauro Numico
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

All authors read and approved the paper, met the criteria for authorship as established by the International Committee of Medical Journals Editors, believe that the paper represents honest work, have full control of all primary data, and are able to verify the validity of the results reported.

Corresponding author

Correspondence to Jacopo Davide Giamello.

Ethics declarations

Conflict of interest

The authors declare no competing interests.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Antonuzzo, Bossi and Numico: *On behalf of Network Italiano Cure di Supporto in Oncologia (NICSO)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Giamello, J.D., Lauria, G., Antonuzzo, A. et al. A nationwide survey among emergency physicians and oncologists to improve the management of immune checkpoint inhibitors toxicity. Support Care Cancer 30, 6365–6368 (2022). https://doi.org/10.1007/s00520-022-06844-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00520-022-06844-7

Search

Navigation